VOLTAREN-XR Drug Patent Profile
✉ Email this page to a colleague
When do Voltaren-xr patents expire, and when can generic versions of Voltaren-xr launch?
Voltaren-xr is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in VOLTAREN-XR is diclofenac sodium. There are forty-seven drug master file entries for this compound. One hundred and twenty-eight suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Voltaren-xr
A generic version of VOLTAREN-XR was approved as diclofenac sodium by ACTAVIS ELIZABETH on March 26th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for VOLTAREN-XR?
- What are the global sales for VOLTAREN-XR?
- What is Average Wholesale Price for VOLTAREN-XR?
Summary for VOLTAREN-XR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 121 |
| Clinical Trials: | 56 |
| Patent Applications: | 3,834 |
| DailyMed Link: | VOLTAREN-XR at DailyMed |
Recent Clinical Trials for VOLTAREN-XR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Washington State University | Early Phase 1 |
| University of Rijeka | N/A |
| Cairo University | Phase 2 |
US Patents and Regulatory Information for VOLTAREN-XR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | VOLTAREN-XR | diclofenac sodium | TABLET, EXTENDED RELEASE;ORAL | 020254-001 | Mar 8, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
